# Tarsus Pharmaceuticals, Inc.: financial statements, quarterly

TARS · Nasdaq · CIK 1819790 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tars.md) · [Financials](/companies/tars/financials.md) · [Filings](/companies/tars/filings.md) · [Insiders](/companies/tars/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tars/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.9](/filings/0001819790-24-000129.md) | [13.1 d](/filings/0001819790-26-000019.md) | [27.6](/filings/0001819790-25-000078.md) | [40.8](/filings/0001819790-25-000108.md) | [48.1](/filings/0001819790-25-000121.md) | [66.4 d](/filings/0001819790-26-000019.md) | [78.3](/filings/0001819790-26-000038.md) | [103](/filings/0001819790-26-000064.md) | [119](/filings/0001819790-25-000121.md) | [152 d](/filings/0001819790-26-000019.md) | [162](/filings/0001819790-26-000038.md) | [174](/filings/0001819790-26-000064.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [5.2](/filings/0001819790-26-000038.md) | [6.2](/filings/0001819790-26-000064.md) | not reported | not reported | [9.4](/filings/0001819790-26-000038.md) | [12.1](/filings/0001819790-26-000064.md) |
| Research and development | $m | [12.1](/filings/0001819790-24-000129.md) | [13.3 d](/filings/0001819790-26-000019.md) | [12.1](/filings/0001819790-25-000078.md) | [12.3](/filings/0001819790-25-000108.md) | [12.1](/filings/0001819790-25-000121.md) | [16.9 d](/filings/0001819790-26-000019.md) | [14.4](/filings/0001819790-26-000038.md) | [15.6](/filings/0001819790-26-000064.md) | [16.3](/filings/0001819790-25-000121.md) | [18.0 d](/filings/0001819790-26-000019.md) | [22.4](/filings/0001819790-26-000038.md) | [31.0](/filings/0001819790-26-000064.md) |
| Selling, general and administrative | $m | not reported | not reported | [51.6](/filings/0001819790-25-000078.md) | [58.8](/filings/0001819790-25-000108.md) | [57.9](/filings/0001819790-25-000121.md) | [69.0 d](/filings/0001819790-26-000019.md) | [85.0](/filings/0001819790-26-000038.md) | [103](/filings/0001819790-26-000064.md) | [109](/filings/0001819790-25-000121.md) | [131 d](/filings/0001819790-26-000019.md) | [136](/filings/0001819790-26-000038.md) | [151](/filings/0001819790-26-000064.md) |
| Operating income | $m | [(40.9)](/filings/0001819790-24-000129.md) | [(44.5) d](/filings/0001819790-26-000019.md) | [(37.7)](/filings/0001819790-25-000078.md) | [(33.3)](/filings/0001819790-25-000108.md) | [(25.2)](/filings/0001819790-25-000121.md) | [(24.4) d](/filings/0001819790-26-000019.md) | [(26.3)](/filings/0001819790-26-000038.md) | [(22.2)](/filings/0001819790-26-000064.md) | [(14.5)](/filings/0001819790-25-000121.md) | [(8.0) d](/filings/0001819790-26-000019.md) | [(6.1)](/filings/0001819790-26-000038.md) | [(19.9)](/filings/0001819790-26-000064.md) |
| Interest expense | $m | [0.9](/filings/0001819790-23-000080.md) | [1.0 d](/filings/0001819790-24-000018.md) | [1.0](/filings/0001819790-24-000063.md) | [2.1](/filings/0001819790-25-000108.md) | [2.4](/filings/0001819790-25-000121.md) | [2.3 d](/filings/0001819790-26-000019.md) | [2.2](/filings/0001819790-26-000038.md) | [2.2](/filings/0001819790-26-000064.md) | [2.3](/filings/0001819790-25-000121.md) | [2.2 d](/filings/0001819790-26-000019.md) | [2.1](/filings/0001819790-26-000038.md) | [2.2](/filings/0001819790-26-000064.md) |
| Income tax | $m | [0.0](/filings/0001819790-23-000080.md) | [0.0 d](/filings/0001819790-26-000019.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001819790-26-000038.md) | [0.0](/filings/0001819790-26-000064.md) | not reported | not reported | [2.4](/filings/0001819790-26-000038.md) | [2.7](/filings/0001819790-26-000064.md) |
| Net income | $m | [(39.1)](/filings/0001819790-24-000129.md) | [(41.9) d](/filings/0001819790-26-000019.md) | [(35.7)](/filings/0001819790-25-000121.md) | [(33.3)](/filings/0001819790-25-000121.md) | [(23.4)](/filings/0001819790-25-000121.md) | [(23.1) d](/filings/0001819790-26-000019.md) | [(25.1)](/filings/0001819790-26-000064.md) | [(20.3)](/filings/0001819790-26-000064.md) | [(12.6)](/filings/0001819790-25-000121.md) | [(8.4) d](/filings/0001819790-26-000019.md) | [(7.0)](/filings/0001819790-26-000064.md) | [(18.6)](/filings/0001819790-26-000064.md) |
| Diluted EPS | $ per share | [(1.28)](/filings/0001819790-24-000129.md) | not reported | [(1.01)](/filings/0001819790-25-000078.md) | [(0.88)](/filings/0001819790-25-000108.md) | [(0.61)](/filings/0001819790-25-000121.md) | not reported | [(0.64)](/filings/0001819790-26-000038.md) | [(0.48)](/filings/0001819790-26-000064.md) | [(0.30)](/filings/0001819790-25-000121.md) | not reported | [(0.16)](/filings/0001819790-26-000038.md) | [(0.43)](/filings/0001819790-26-000064.md) |
| Basic EPS | $ per share | [(1.28)](/filings/0001819790-24-000129.md) | not reported | [(1.01)](/filings/0001819790-25-000078.md) | [(0.88)](/filings/0001819790-25-000108.md) | [(0.61)](/filings/0001819790-25-000121.md) | not reported | [(0.64)](/filings/0001819790-26-000038.md) | [(0.48)](/filings/0001819790-26-000064.md) | [(0.30)](/filings/0001819790-25-000121.md) | not reported | [(0.16)](/filings/0001819790-26-000038.md) | [(0.43)](/filings/0001819790-26-000064.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [227](/filings/0001819790-23-000080.md) | [225](/filings/0001819790-25-000011.md) | [194](/filings/0001819790-24-000063.md) | [181](/filings/0001819790-24-000111.md) | [176](/filings/0001819790-24-000129.md) | [94.8](/filings/0001819790-26-000019.md) | [176](/filings/0001819790-25-000078.md) | [96.6](/filings/0001819790-25-000108.md) | [113](/filings/0001819790-25-000121.md) | [184](/filings/0001819790-26-000064.md) | [102](/filings/0001819790-26-000038.md) | [205](/filings/0001819790-26-000064.md) |
| Current assets | $m | [259](/filings/0001819790-23-000080.md) | [256](/filings/0001819790-25-000011.md) | [341](/filings/0001819790-24-000063.md) | [363](/filings/0001819790-24-000111.md) | [357](/filings/0001819790-24-000129.md) | [357](/filings/0001819790-26-000019.md) | [481](/filings/0001819790-25-000078.md) | [474](/filings/0001819790-25-000108.md) | [502](/filings/0001819790-25-000121.md) | [523](/filings/0001819790-26-000064.md) | [537](/filings/0001819790-26-000038.md) | [562](/filings/0001819790-26-000064.md) |
| Total assets | $m | [268](/filings/0001819790-23-000080.md) | [265](/filings/0001819790-25-000011.md) | [349](/filings/0001819790-24-000063.md) | [377](/filings/0001819790-24-000111.md) | [376](/filings/0001819790-24-000129.md) | [377](/filings/0001819790-26-000019.md) | [501](/filings/0001819790-25-000078.md) | [495](/filings/0001819790-25-000108.md) | [535](/filings/0001819790-25-000121.md) | [562](/filings/0001819790-26-000064.md) | [581](/filings/0001819790-26-000038.md) | [611](/filings/0001819790-26-000064.md) |
| Current liabilities | $m | [23.2](/filings/0001819790-23-000080.md) | [36.9](/filings/0001819790-25-000011.md) | [42.5](/filings/0001819790-24-000063.md) | [51.6](/filings/0001819790-24-000111.md) | [65.9](/filings/0001819790-24-000129.md) | [80.6](/filings/0001819790-26-000019.md) | [86.3](/filings/0001819790-25-000078.md) | [90.3](/filings/0001819790-25-000108.md) | [117](/filings/0001819790-25-000121.md) | [136](/filings/0001819790-26-000064.md) | [144](/filings/0001819790-26-000038.md) | [176](/filings/0001819790-26-000064.md) |
| Total liabilities | $m | [54.7](/filings/0001819790-23-000080.md) | [68.5](/filings/0001819790-25-000011.md) | [74.1](/filings/0001819790-24-000063.md) | [125](/filings/0001819790-24-000111.md) | [139](/filings/0001819790-24-000129.md) | [152](/filings/0001819790-26-000019.md) | [158](/filings/0001819790-25-000078.md) | [162](/filings/0001819790-25-000108.md) | [199](/filings/0001819790-25-000121.md) | [219](/filings/0001819790-26-000064.md) | [232](/filings/0001819790-26-000038.md) | [264](/filings/0001819790-26-000064.md) |
| Long-term debt | $m | [29.7](/filings/0001819790-23-000080.md) | [29.8](/filings/0001819790-25-000011.md) | [29.9](/filings/0001819790-24-000063.md) | [71.6](/filings/0001819790-24-000111.md) | [71.7](/filings/0001819790-24-000129.md) | [71.8](/filings/0001819790-26-000019.md) | [72.0](/filings/0001819790-25-000078.md) | [72.1](/filings/0001819790-25-000108.md) | [72.3](/filings/0001819790-25-000121.md) | [72.4](/filings/0001819790-26-000064.md) | [72.6](/filings/0001819790-26-000038.md) | [72.8](/filings/0001819790-26-000064.md) |
| Shareholders' equity | $m | [214](/filings/0001819790-24-000129.md) | [197](/filings/0001819790-26-000019.md) | [275](/filings/0001819790-25-000121.md) | [252](/filings/0001819790-25-000121.md) | [237](/filings/0001819790-25-000121.md) | [225](/filings/0001819790-26-000064.md) | [342](/filings/0001819790-26-000064.md) | [333](/filings/0001819790-26-000064.md) | [335](/filings/0001819790-25-000121.md) | [343](/filings/0001819790-26-000064.md) | [349](/filings/0001819790-26-000064.md) | [347](/filings/0001819790-26-000064.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(32.4) d](/filings/0001819790-24-000129.md) | [(39.3) d](/filings/0001819790-26-000019.md) | [(37.8)](/filings/0001819790-25-000078.md) | [(14.4) d](/filings/0001819790-25-000108.md) | [(8.7) d](/filings/0001819790-25-000121.md) | [(22.2) d](/filings/0001819790-26-000019.md) | [(20.7)](/filings/0001819790-26-000038.md) | [(29.4) d](/filings/0001819790-26-000064.md) | [18.3 d](/filings/0001819790-25-000121.md) | [19.3 d](/filings/0001819790-26-000019.md) | [(24.7)](/filings/0001819790-26-000038.md) | [61.2 d](/filings/0001819790-26-000064.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001819790-24-000129.md) | [0.0 d](/filings/0001819790-26-000019.md) | [0.2](/filings/0001819790-25-000078.md) | [1.0 d](/filings/0001819790-25-000108.md) | [0.3 d](/filings/0001819790-25-000121.md) | [0.1 d](/filings/0001819790-26-000019.md) | [0.6](/filings/0001819790-26-000038.md) | [1.0 d](/filings/0001819790-26-000064.md) | [1.9 d](/filings/0001819790-25-000121.md) | [6.4 d](/filings/0001819790-26-000019.md) | [5.8](/filings/0001819790-26-000038.md) | [4.1 d](/filings/0001819790-26-000064.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [26.7](/filings/0001819790-23-000080.md) | [26.7](/filings/0001819790-24-000063.md) | [26.8](/filings/0001819790-24-000111.md) | [30.6](/filings/0001819790-24-000129.md) | [35.3](/filings/0001819790-25-000078.md) | [37.8](/filings/0001819790-25-000108.md) | [38.4](/filings/0001819790-25-000121.md) | [39.3](/filings/0001819790-26-000038.md) | [42.4](/filings/0001819790-26-000064.md) | [42.6](/filings/0001819790-25-000121.md) | [43.0](/filings/0001819790-26-000038.md) | [43.4](/filings/0001819790-26-000064.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 43,882,996 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001819790-26-000064.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.